Teva Pharmaceutical Industries Limited (NYSE:TEVA) Short Interest Up 25.1% in March

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 34,800,000 shares, an increase of 25.1% from the February 28th total of 27,810,000 shares. Based on an average daily volume of 12,260,000 shares, the days-to-cover ratio is presently 2.8 days. Currently, 3.1% of the company’s shares are sold short.

Analyst Ratings Changes

A number of research firms recently commented on TEVA. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday, March 27th. Piper Sandler raised their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Bank of America lowered their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Barclays reduced their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Finally, UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Stock Up 0.1 %

Shares of Teva Pharmaceutical Industries stock traded up $0.02 during midday trading on Wednesday, hitting $15.31. The company had a trading volume of 7,736,317 shares, compared to its average volume of 9,691,913. The company has a 50 day moving average of $16.95 and a 200 day moving average of $18.08. The stock has a market capitalization of $17.36 billion, a P/E ratio of -10.56, a P/E/G ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries has a 52-week low of $12.51 and a 52-week high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, equities analysts predict that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Wellington Management Group LLP grew its stake in shares of Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Wellington Management Group LLP now owns 185,912 shares of the company’s stock worth $4,098,000 after acquiring an additional 3,816 shares during the period. Centaurus Financial Inc. raised its stake in Teva Pharmaceutical Industries by 97.2% during the 4th quarter. Centaurus Financial Inc. now owns 35,279 shares of the company’s stock valued at $778,000 after buying an additional 17,388 shares during the last quarter. Siemens Fonds Invest GmbH bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $611,000. Jefferies Financial Group Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter worth $332,000. Finally, Capital A Wealth Management LLC purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at $596,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.